• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

载脂蛋白与脂质体的串扰作为将 5-氟尿嘧啶靶向递送至肝细胞的范例:细胞毒性和肝脏沉积。

Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition.

机构信息

Kayyali Chair for Pharmaceutical Industries, Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Pharmaceutical Care Services, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.

出版信息

Bioengineered. 2021 Dec;12(1):914-926. doi: 10.1080/21655979.2021.1896202.

DOI:10.1080/21655979.2021.1896202
PMID:33678142
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8806320/
Abstract

This study aimed to utilize cholesterol conjugation of 5-fluorouracil (5-FUC) and liposomal formulas to enhance the partitioning of 5-FU into low density lipoprotein (LDL) to target hepatocellular carcinoma (HCC). Thus, 5-FU and 5-FUCwere loaded into liposomes. Later, the direct loading and transfer of 5-FU, and 5-FUC from liposomes into LDL were attained. The preparations were characterized in terms of particle size, zeta potential, morphology, entrapment efficiency, and cytotoxicity using the HepG2 cell line. Moreover, the drug deposition into the LDL and liver tissues was investigated. The present results revealed that liposomal preparations have a nanosize range (155 - 194 nm), negative zeta potential (- 0.82 to - 16 mV), entrapment efficiency of 69% for 5-FU, and 66% for 5-FUC. Moreover, LDL particles have a nanosize range (28-49 nm), negative zeta potential (- 17 to -27 mV), and the entrapment efficiency is 11% for 5-FU and 85% for 5-FUC. Furthermore, 5-FUC loaded liposomes displayed a sustained release profile (57%) at 24 h compared to fast release (92%) of 5-FU loaded liposomes. 5-FUC and liposomal formulas enhanced the transfer of 5-FUC into LDL compared to 5-FU. 5-FUC loaded liposomes and LDL have greater cytotoxicity against HepG2 cell lines compared to 5-FU and 5-FUC solutions. Moreover, the deposition of 5-FUC in LDL (26.87ng/mg) and liver tissues (534 ng/gm tissue) was significantly increased 5-FUC liposomes compared to 5-FU (11.7 ng/g tissue) liposomal formulation. In conclusion, 5-FUC is a promising strategy for hepatic targeting of 5-FU through LDL-mediated gateway.

摘要

本研究旨在利用 5-氟尿嘧啶(5-FU)的胆固醇缀合和脂质体配方将 5-FU 分配到低密度脂蛋白(LDL)中,以靶向肝细胞癌(HCC)。因此,将 5-FU 和 5-FUC 载入脂质体。随后,直接载入并将 5-FU 和 5-FUC 从脂质体转移到 LDL 中。使用 HepG2 细胞系,根据粒径、zeta 电位、形态、包封效率和细胞毒性对制剂进行了表征。此外,还研究了药物在 LDL 和肝组织中的沉积。结果表明,脂质体制剂的纳米尺寸范围为(155-194nm),zeta 电位为负(-0.82 至-16mV),5-FU 的包封效率为 69%,5-FUC 的包封效率为 66%。此外,LDL 颗粒的纳米尺寸范围为(28-49nm),zeta 电位为负(-17 至-27mV),5-FU 的包封效率为 11%,5-FUC 的包封效率为 85%。此外,与 5-FU 载脂质体快速释放(92%)相比,5-FUC 载脂质体在 24 小时时显示出持续释放(57%)的特征。与 5-FU 相比,5-FUC 载脂质体和脂质体配方增强了 5-FUC 向 LDL 的转移。与 5-FU 和 5-FUC 溶液相比,5-FUC 载脂质体和 LDL 对 HepG2 细胞系具有更高的细胞毒性。此外,与 5-FU 载脂质体(11.7ng/g 组织)相比,5-FUC 载脂质体在 LDL(26.87ng/mg)和肝组织(534ng/gm 组织)中的沉积显著增加。总之,通过 LDL 介导的途径,5-FUC 是将 5-FU 靶向肝脏的一种很有前途的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d129/8806320/5b257f6844b7/KBIE_A_1896202_F0006_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d129/8806320/df94a24a3322/KBIE_A_1896202_UF0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d129/8806320/88a3fa2a2441/KBIE_A_1896202_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d129/8806320/7586f03cd64f/KBIE_A_1896202_F0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d129/8806320/5e976f884631/KBIE_A_1896202_F0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d129/8806320/8b0d7e499d83/KBIE_A_1896202_F0004_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d129/8806320/22d1cdef7c64/KBIE_A_1896202_F0005_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d129/8806320/5b257f6844b7/KBIE_A_1896202_F0006_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d129/8806320/df94a24a3322/KBIE_A_1896202_UF0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d129/8806320/88a3fa2a2441/KBIE_A_1896202_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d129/8806320/7586f03cd64f/KBIE_A_1896202_F0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d129/8806320/5e976f884631/KBIE_A_1896202_F0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d129/8806320/8b0d7e499d83/KBIE_A_1896202_F0004_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d129/8806320/22d1cdef7c64/KBIE_A_1896202_F0005_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d129/8806320/5b257f6844b7/KBIE_A_1896202_F0006_B.jpg

相似文献

1
Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition.载脂蛋白与脂质体的串扰作为将 5-氟尿嘧啶靶向递送至肝细胞的范例:细胞毒性和肝脏沉积。
Bioengineered. 2021 Dec;12(1):914-926. doi: 10.1080/21655979.2021.1896202.
2
Cholesterol-Conjugate as a New Strategy to Improve the Cytotoxic Effect of 5-Fluorouracil on Liver Cancer: Impact of Liposomal Composition.胆固醇缀合物作为提高氟尿嘧啶对肝癌细胞毒性作用的新策略:脂质体组成的影响。
Curr Drug Deliv. 2020;17(10):898-910. doi: 10.2174/1567201817666200211095452.
3
Nano-erythrocyte membrane-chaperoned 5-fluorouracil liposomes as biomimetic delivery platforms to target hepatocellular carcinoma cell lines.纳米红细胞膜包裹的 5-氟尿嘧啶脂质体作为仿生递药平台靶向肝癌细胞系。
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):989-996. doi: 10.1080/21691401.2019.1577887.
4
Design of cholesterol arabinogalactan anchored liposomes for asialoglycoprotein receptor mediated targeting to hepatocellular carcinoma: In silico modeling, in vitro and in vivo evaluation.载胆固醇阿拉伯半乳糖聚糖的脂质体用于通过去唾液酸糖蛋白受体介导的靶向肝癌:计算机建模、体外和体内评价。
Int J Pharm. 2016 Jul 25;509(1-2):149-158. doi: 10.1016/j.ijpharm.2016.05.041. Epub 2016 May 23.
5
Therapeutic targeting of siRNA/anti-cancer drug delivery system for non-melanoma skin cancer. Part I: Development and gene silencing of JAK1siRNA/5-FU loaded liposome nanocomplexes.针对非黑色素瘤皮肤癌的 siRNA/抗癌药物递送系统的治疗靶向。第一部分:JAK1siRNA/5-FU 负载脂质体纳米复合物的开发和基因沉默。
Eur J Pharm Biopharm. 2024 Oct;203:114432. doi: 10.1016/j.ejpb.2024.114432. Epub 2024 Aug 2.
6
Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells.叶酸修饰脂质体的设计与开发,用于增强5-氟尿嘧啶向肿瘤细胞的递送。
J Drug Target. 2007 Apr;15(3):231-40. doi: 10.1080/10611860701289719.
7
Mannose Conjugated Starch Nanoparticles for Preferential Targeting of Liver Cancer.甘露糖偶联淀粉纳米粒用于肝癌的靶向治疗。
Curr Drug Deliv. 2021;18(3):369-380. doi: 10.2174/1567201817666200903171124.
8
Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in-vitro release, and cytotoxicity analysis.传递体、脂质体和非离子型脂质体用于 5-氟尿嘧啶经皮递送至皮肤癌细胞的比较研究:制备、表征、体外释放和细胞毒性分析。
Anticancer Drugs. 2011 Sep;22(8):774-82. doi: 10.1097/CAD.0b013e328346c7d6.
9
Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma.靶向载 5-氟尿嘧啶和硝呋米特(组织蛋白酶 B 抑制剂)纳米粒用于肝癌 HepG2 细胞的共递药。
Anticancer Agents Med Chem. 2020;20(3):346-358. doi: 10.2174/1871520619666190930124746.
10
Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells.组蛋白去乙酰化酶抑制剂激活的p53通过诱导肝癌细胞中岩藻糖基转移酶8的表达增强L-岩藻糖介导的药物递送
PLoS One. 2016 Dec 15;11(12):e0168355. doi: 10.1371/journal.pone.0168355. eCollection 2016.

引用本文的文献

1
Chitosan capped-NLCs enhanced codelivery of gefitinib and simvastatin into MDR HCC: impact of compositions on cell death, JNK3, and Telomerase.壳聚糖包覆的纳米脂质载体增强吉非替尼和辛伐他汀向多药耐药性肝癌细胞的共递送:组合物对细胞死亡、JNK3和端粒酶的影响
Oncol Res. 2025 Jan 16;33(2):477-492. doi: 10.32604/or.2024.053337. eCollection 2025.
2
A Coarse-Grained Molecular Dynamics Perspective on the Release of 5-Fluorouracil from Liposomes.从粗粒度分子动力学角度看5-氟尿嘧啶从脂质体中的释放
Mol Pharm. 2024 Dec 2;21(12):6137-6152. doi: 10.1021/acs.molpharmaceut.4c00328. Epub 2024 Nov 8.
3
Chitosan-enclosed SLN improved SV-induced hepatocellular cell carcinoma death by modulation of IQGAP gene expression, JNK, and HDAC activities.

本文引用的文献

1
Low density lipoprotein mimic nanoparticles composed of amphipathic hybrid peptides and lipids for tumor-targeted delivery of paclitaxel.由两亲性杂合肽和脂质组成的模拟低密度脂蛋白纳米颗粒,用于紫杉醇的肿瘤靶向递送。
Int J Nanomedicine. 2019 Sep 11;14:7431-7446. doi: 10.2147/IJN.S215080. eCollection 2019.
2
Nano-erythrocyte membrane-chaperoned 5-fluorouracil liposomes as biomimetic delivery platforms to target hepatocellular carcinoma cell lines.纳米红细胞膜包裹的 5-氟尿嘧啶脂质体作为仿生递药平台靶向肝癌细胞系。
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):989-996. doi: 10.1080/21691401.2019.1577887.
3
Chitosan-Coated Flexible Liposomes Magnify the Anticancer Activity and Bioavailability of Docetaxel: Impact on Composition.
壳聚糖包裹的固体脂质纳米粒通过调节IQGAP基因表达、JNK和组蛋白去乙酰化酶活性,增强了喜树碱诱导的肝癌细胞死亡。
Mol Biol Rep. 2024 Jul 18;51(1):824. doi: 10.1007/s11033-024-09757-2.
4
Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer.纳米脂质体在肝癌诊断和治疗中的研究进展。
Int J Nanomedicine. 2022 Feb 26;17:909-925. doi: 10.2147/IJN.S349426. eCollection 2022.
5
Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances.基于脂质的纳米颗粒作为一种新型的肝细胞癌治疗方法:靶向和最新进展的综合综述。
J Nanobiotechnology. 2022 Mar 5;20(1):109. doi: 10.1186/s12951-022-01309-9.
壳聚糖包被的柔性脂质体放大多西紫杉醇的抗癌活性和生物利用度:对组成的影响。
Molecules. 2019 Jan 11;24(2):250. doi: 10.3390/molecules24020250.
4
Natural low- and high-density lipoproteins as mighty bio-nanocarriers for anticancer drug delivery.天然低、高密度脂蛋白作为强大的生物纳米载体用于抗癌药物递送。
Cancer Chemother Pharmacol. 2018 Sep;82(3):371-382. doi: 10.1007/s00280-018-3626-4. Epub 2018 Jun 18.
5
Low-Density Lipoproteins and Human Serum Albumin as Carriers of Squalenoylated Drugs: Insights from Molecular Simulations.低密度脂蛋白和人血清白蛋白作为鲨烯酰化药物的载体:分子模拟的见解。
Mol Pharm. 2018 Feb 5;15(2):585-591. doi: 10.1021/acs.molpharmaceut.7b00952. Epub 2018 Jan 17.
6
Inorganic Kernel-Reconstituted Lipoprotein Biomimetic Nanovehicles Enable Efficient Targeting "Trojan Horse" Delivery of STAT3-Decoy Oligonucleotide for Overcoming TRAIL Resistance.无机核重构脂蛋白仿生纳米载体实现高效靶向“特洛伊木马”递送信号转导与转录激活因子3(STAT3)诱饵寡核苷酸以克服肿瘤坏死因子相关凋亡诱导配体(TRAIL)耐药性。
Theranostics. 2017 Oct 12;7(18):4480-4497. doi: 10.7150/thno.21707. eCollection 2017.
7
Involvement of scavenger receptor class B type 1 and low-density lipoprotein receptor in the internalization of liposomes into HepG2 cells.清道夫受体 B 类 1 型和低密度脂蛋白受体在 HepG2 细胞内化脂质体中的作用。
Biochim Biophys Acta Biomembr. 2017 Nov;1859(11):2253-2258. doi: 10.1016/j.bbamem.2017.09.005. Epub 2017 Sep 6.
8
Chemotherapy for hepatocellular carcinoma: The present and the future.肝细胞癌的化疗:现状与未来
World J Hepatol. 2017 Jul 28;9(21):907-920. doi: 10.4254/wjh.v9.i21.907.
9
An overview of nanosomes delivery mechanisms: trafficking, orders, barriers and cellular effects.纳米囊泡递药机制概述:转运、内吞、屏障和细胞效应。
Artif Cells Nanomed Biotechnol. 2018 Jun;46(4):669-679. doi: 10.1080/21691401.2017.1354301. Epub 2017 Jul 13.
10
Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells.循环脂蛋白:引导鲨烯化药物进入低密度脂蛋白聚集癌细胞的特洛伊木马。
Mol Ther. 2017 Jul 5;25(7):1596-1605. doi: 10.1016/j.ymthe.2017.05.016. Epub 2017 Jun 9.